Sofgen Pharma S.A.
PROCF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.8M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $2.80 Million |
|---|---|
| Enterprise Value | $314.60 Million |
| Earnings per Share | $0.4 |
| Beta | 8.92 |
| Outstanding Shares | 112,170,399 |
Return
| Return on Equity | 19211.43% |
|---|---|
| Return on Assets | 8.54% |
| Return on Invested Capital | 73.40% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | 0.01 |
| Price to Book Ratio | -0.03 |
| Enterprise Value to Revenue | 0.74 |
| Enterprise Value to EBIT | 6.05 |
| Enterprise Value to Net Income | 7 |
| Total Debt to Enterprise | 1.05 |
| Debt to Equity | 1568.16 |
Revenue Sources
No data
Last Earnings Call
Report Date
September 8, 2026
EPS Estimate
$0.16
Consensus analyst estimateRevenue Estimate
$135.70 M
Consensus analyst estimateNext Earnings Call
Expected Date
December 30, 2026
EPS Estimate
$0.16
Consensus analyst estimateRevenue Estimate
$135.70 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Procaps Group S.A
4,498 employees
CEO: Ruben Minski
Procaps Group S.A. is a global pharmaceutical company engaged in the development, manufacturing, and commercialization of a diverse range of medical solutions. The company's portfolio encompasses branded prescription drugs, addressing nu...